Optimization of Novel Antagonists to the Neurokinin‑3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)

Optimization of Novel Antagonists to the Neurokinin‑3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)

Further lead optimization on N-acyl-triazolopiperazine antagonists to the neurokinin-3 receptor (NK3R) based on the concurrent improvement in bioactivity and ligand lipophilic efficiency (LLE) is reported. Overall, compound 3 (LLE > 6) emerged as the most efficacious in castrated rat and monkey t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS medicinal chemistry letters 2015-07, Vol.6 (7), p.736-740
Hauptverfasser: Hoveyda, Hamid R, Fraser, Graeme L, Dutheuil, Guillaume, El Bousmaqui, Mohamed, Korac, Julien, Lenoir, François, Lapin, Alexey, Noël, Sophie
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 740
container_issue 7
container_start_page 736
container_title ACS medicinal chemistry letters
container_volume 6
creator Hoveyda, Hamid R
Fraser, Graeme L
Dutheuil, Guillaume
El Bousmaqui, Mohamed
Korac, Julien
Lenoir, François
Lapin, Alexey
Noël, Sophie
description Further lead optimization on N-acyl-triazolopiperazine antagonists to the neurokinin-3 receptor (NK3R) based on the concurrent improvement in bioactivity and ligand lipophilic efficiency (LLE) is reported. Overall, compound 3 (LLE > 6) emerged as the most efficacious in castrated rat and monkey to lower plasma LH, and it displayed the best off-target safety profile that led to its clinical candidate nomination for the treatment of sex-hormone disorders.
doi_str_mv 10.1021/acsmedchemlett.5b00117
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4499830</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1697752204</sourcerecordid><originalsourceid>FETCH-LOGICAL-a523t-21b4471ddc215fd676d1f1fc89df57e85797ef0ccaf34de1992cbe5f7a2bf1bf3</originalsourceid><addsrcrecordid>eNqFkcFO3DAQhq0KVCjtKyAf6SHUduI4vlRCQMtKCBClZ8txxqxpYm9tB9Ge-gp9xT5JE-2C4MRh5JHmn8-j_0don5JDShj9pE0aoDNLGHrI-ZC3hFAq3qBdKqum4I3gW8_6HfQupTtCaikEeYt2WE0lLXmzi8bLVXaD-62zCx4Hiy_CPfT4yGd9G7xLOeEccF4CvoAxhh_OO__vz98SX4OBVQ4R26nm-U0EnQfweaZ8g4fiLMQheMAnLoXYQUz44ErHjBeLj-_RttV9gg-bdw99_3J6c3xWnF9-XRwfnReaszIXjLZVJWjXGUa57WpRd9RSaxrZWS6g4UIKsMQYbcuqAyolMy1wKzRrLW1tuYc-r7mrsZ3tmq6Luler6AYdf6mgnXo58W6pbsO9qiopm5JMgIMNIIafI6SsBpcM9L32EMak6OwoZ4xUk7ReS00MKUWwT99QoubM1MvM1CazaXH_-ZFPa48hTQK2FkwAdRfG6CfPXqP-B25SrOk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1697752204</pqid></control><display><type>article</type><title>Optimization of Novel Antagonists to the Neurokinin‑3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)</title><source>ACS Publications</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Hoveyda, Hamid R ; Fraser, Graeme L ; Dutheuil, Guillaume ; El Bousmaqui, Mohamed ; Korac, Julien ; Lenoir, François ; Lapin, Alexey ; Noël, Sophie</creator><creatorcontrib>Hoveyda, Hamid R ; Fraser, Graeme L ; Dutheuil, Guillaume ; El Bousmaqui, Mohamed ; Korac, Julien ; Lenoir, François ; Lapin, Alexey ; Noël, Sophie</creatorcontrib><description>Further lead optimization on N-acyl-triazolopiperazine antagonists to the neurokinin-3 receptor (NK3R) based on the concurrent improvement in bioactivity and ligand lipophilic efficiency (LLE) is reported. Overall, compound 3 (LLE &gt; 6) emerged as the most efficacious in castrated rat and monkey to lower plasma LH, and it displayed the best off-target safety profile that led to its clinical candidate nomination for the treatment of sex-hormone disorders.</description><identifier>ISSN: 1948-5875</identifier><identifier>EISSN: 1948-5875</identifier><identifier>DOI: 10.1021/acsmedchemlett.5b00117</identifier><identifier>PMID: 26191358</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><ispartof>ACS medicinal chemistry letters, 2015-07, Vol.6 (7), p.736-740</ispartof><rights>Copyright © 2015 American Chemical Society</rights><rights>Copyright © 2015 American Chemical Society 2015 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a523t-21b4471ddc215fd676d1f1fc89df57e85797ef0ccaf34de1992cbe5f7a2bf1bf3</citedby><cites>FETCH-LOGICAL-a523t-21b4471ddc215fd676d1f1fc89df57e85797ef0ccaf34de1992cbe5f7a2bf1bf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.5b00117$$EPDF$$P50$$Gacs$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acsmedchemlett.5b00117$$EHTML$$P50$$Gacs$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,2752,27055,27903,27904,53769,53771,56716,56766</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26191358$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoveyda, Hamid R</creatorcontrib><creatorcontrib>Fraser, Graeme L</creatorcontrib><creatorcontrib>Dutheuil, Guillaume</creatorcontrib><creatorcontrib>El Bousmaqui, Mohamed</creatorcontrib><creatorcontrib>Korac, Julien</creatorcontrib><creatorcontrib>Lenoir, François</creatorcontrib><creatorcontrib>Lapin, Alexey</creatorcontrib><creatorcontrib>Noël, Sophie</creatorcontrib><title>Optimization of Novel Antagonists to the Neurokinin‑3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)</title><title>ACS medicinal chemistry letters</title><addtitle>ACS Med. Chem. Lett</addtitle><description>Further lead optimization on N-acyl-triazolopiperazine antagonists to the neurokinin-3 receptor (NK3R) based on the concurrent improvement in bioactivity and ligand lipophilic efficiency (LLE) is reported. Overall, compound 3 (LLE &gt; 6) emerged as the most efficacious in castrated rat and monkey to lower plasma LH, and it displayed the best off-target safety profile that led to its clinical candidate nomination for the treatment of sex-hormone disorders.</description><issn>1948-5875</issn><issn>1948-5875</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>N~.</sourceid><recordid>eNqFkcFO3DAQhq0KVCjtKyAf6SHUduI4vlRCQMtKCBClZ8txxqxpYm9tB9Ge-gp9xT5JE-2C4MRh5JHmn8-j_0don5JDShj9pE0aoDNLGHrI-ZC3hFAq3qBdKqum4I3gW8_6HfQupTtCaikEeYt2WE0lLXmzi8bLVXaD-62zCx4Hiy_CPfT4yGd9G7xLOeEccF4CvoAxhh_OO__vz98SX4OBVQ4R26nm-U0EnQfweaZ8g4fiLMQheMAnLoXYQUz44ErHjBeLj-_RttV9gg-bdw99_3J6c3xWnF9-XRwfnReaszIXjLZVJWjXGUa57WpRd9RSaxrZWS6g4UIKsMQYbcuqAyolMy1wKzRrLW1tuYc-r7mrsZ3tmq6Luler6AYdf6mgnXo58W6pbsO9qiopm5JMgIMNIIafI6SsBpcM9L32EMak6OwoZ4xUk7ReS00MKUWwT99QoubM1MvM1CazaXH_-ZFPa48hTQK2FkwAdRfG6CfPXqP-B25SrOk</recordid><startdate>20150709</startdate><enddate>20150709</enddate><creator>Hoveyda, Hamid R</creator><creator>Fraser, Graeme L</creator><creator>Dutheuil, Guillaume</creator><creator>El Bousmaqui, Mohamed</creator><creator>Korac, Julien</creator><creator>Lenoir, François</creator><creator>Lapin, Alexey</creator><creator>Noël, Sophie</creator><general>American Chemical Society</general><scope>N~.</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150709</creationdate><title>Optimization of Novel Antagonists to the Neurokinin‑3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)</title><author>Hoveyda, Hamid R ; Fraser, Graeme L ; Dutheuil, Guillaume ; El Bousmaqui, Mohamed ; Korac, Julien ; Lenoir, François ; Lapin, Alexey ; Noël, Sophie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a523t-21b4471ddc215fd676d1f1fc89df57e85797ef0ccaf34de1992cbe5f7a2bf1bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoveyda, Hamid R</creatorcontrib><creatorcontrib>Fraser, Graeme L</creatorcontrib><creatorcontrib>Dutheuil, Guillaume</creatorcontrib><creatorcontrib>El Bousmaqui, Mohamed</creatorcontrib><creatorcontrib>Korac, Julien</creatorcontrib><creatorcontrib>Lenoir, François</creatorcontrib><creatorcontrib>Lapin, Alexey</creatorcontrib><creatorcontrib>Noël, Sophie</creatorcontrib><collection>American Chemical Society (ACS) Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ACS medicinal chemistry letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoveyda, Hamid R</au><au>Fraser, Graeme L</au><au>Dutheuil, Guillaume</au><au>El Bousmaqui, Mohamed</au><au>Korac, Julien</au><au>Lenoir, François</au><au>Lapin, Alexey</au><au>Noël, Sophie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimization of Novel Antagonists to the Neurokinin‑3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)</atitle><jtitle>ACS medicinal chemistry letters</jtitle><addtitle>ACS Med. Chem. Lett</addtitle><date>2015-07-09</date><risdate>2015</risdate><volume>6</volume><issue>7</issue><spage>736</spage><epage>740</epage><pages>736-740</pages><issn>1948-5875</issn><eissn>1948-5875</eissn><abstract>Further lead optimization on N-acyl-triazolopiperazine antagonists to the neurokinin-3 receptor (NK3R) based on the concurrent improvement in bioactivity and ligand lipophilic efficiency (LLE) is reported. Overall, compound 3 (LLE &gt; 6) emerged as the most efficacious in castrated rat and monkey to lower plasma LH, and it displayed the best off-target safety profile that led to its clinical candidate nomination for the treatment of sex-hormone disorders.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>26191358</pmid><doi>10.1021/acsmedchemlett.5b00117</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1948-5875
ispartof ACS medicinal chemistry letters, 2015-07, Vol.6 (7), p.736-740
issn 1948-5875
1948-5875
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4499830
source ACS Publications; EZB-FREE-00999 freely available EZB journals; PubMed Central
title Optimization of Novel Antagonists to the Neurokinin‑3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T15%3A33%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimization%20of%20Novel%20Antagonists%20to%20the%20Neurokinin%E2%80%913%20Receptor%20for%20the%20Treatment%20of%20Sex-Hormone%20Disorders%20(Part%20II)&rft.jtitle=ACS%20medicinal%20chemistry%20letters&rft.au=Hoveyda,%20Hamid%20R&rft.date=2015-07-09&rft.volume=6&rft.issue=7&rft.spage=736&rft.epage=740&rft.pages=736-740&rft.issn=1948-5875&rft.eissn=1948-5875&rft_id=info:doi/10.1021/acsmedchemlett.5b00117&rft_dat=%3Cproquest_pubme%3E1697752204%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1697752204&rft_id=info:pmid/26191358&rfr_iscdi=true